FDA labeling restriction quickly reflected in oncology practice

(HealthDay)—The June 2018 U.S. Food and Drug Administration label restriction on first-line immunotherapy for advanced bladder cancer was associated with a decrease in immunotherapy use and an increase in chemotherapy use, according to a research letter published in the Sept. 24 issue of the Journal of the American Medical Association….